// App-Quantinova.ai

: Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB).

Researchers

Presenter

  • Tanya Jindal

Principal Investigators

  • Li Zhang

  • Kevin R Reyes

  • Prianka Deshmukh

  • Ivan de Kouchkovsky

  • Vipul Kumar

  • Edward Maldonado

  • Chase Shipp

  • Daniel H Kwon

  • Hala Borno

  • Rohit Bose

  • Arpita Desai

  • Rahul Raj Aggarwal

  • Sima P. Porten

  • Eric Jay Small

  • Lawrence Fong

  • Jonathan Chou

  • Terence W. Friedlander

  • Vadim S Koshkin

Medical Centers

  • University of California, San Francisco, San Francisco, CA

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • UCSF Hem/Onc Fellowship, San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Mouse double minute 2 homolog

  • AT-rich interactive domain 1A

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Cyclin Dependent Kinase Inhibitor 2A

  • Cyclin Dependent Kinase Inhibitor 2B

  • Cyclin D1

  • Programmed death-ligand 1

  • Retinoblastoma protein

  • erb-b2 receptor tyrosine kinase 2

  • Fibroblast growth factor 19

  • Fibroblast growth factor receptor 3

  • Tumor protein p53

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved